BCL
BTMD icon

Bracebridge Capital LLC’s Biote Corp BTMD Stock Holding History

Bracebridge Capital LLC’s Portfolio BTMD Stock Details BTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-310,200
Closed -$3.06M – 103
2022
Q1 		$3.06M Buy
+310,200
New +$3.05M 0.23% 36

Other funds holding BTMD

CM
Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return

Bracebridge Capital LLC's BTMD Position: Q2 2022 in Review

Bracebridge Capital LLC sold out of Biote Corp (BTMD) in Q2 2022, closing a stake of 310,200 shares — an estimated $3.06M sold.

Bracebridge Capital LLC first reported a position in BTMD in Q1 2022 and held it in 1 quarter. The position peaked at $3.06M in Q1 2022. 12 funds tracked by Wall St. Rank hold BTMD as of Q2 2022.

  • Bracebridge Capital LLC reported no remaining Biote Corp position as of Q2 2022 after selling out during the quarter.
  • Bracebridge Capital LLC sold 310,200 Biote Corp shares in Q2 2022, an estimated $3.06M.
  • Bracebridge Capital LLC first reported a position in Biote Corp in Q1 2022 and held it in 1 quarter.
  • Bracebridge Capital LLC's Biote Corp position peaked at $3.06M in Q1 2022.
  • 12 funds tracked by Wall St. Rank held Biote Corp as of Q2 2022.

Based on Bracebridge Capital LLC's 13F filing for Q2 2022, filed 8 Aug 2022.